ECE2013 Poster Presentations Cardiovascular Endocrinology & Lipid Metabolism (41 abstracts)
Clinical experience with exenatide and liraglutide in the internal medicine service two of hospitals in Valencia
Juan Jose Tamarit-Garcia 1 , Belen Roig-Espert 2 , Marta Balaguer-Catalan 1 , Amparo Lozano-Cebrian 1 , Ana Ruiz-Garcia 1 , Belen Vizcaino-Castillo 1 , Patricia Sacie-Reyes 1 & Atruro Artero-Mora 1
1Dr Peset University Hospital, Valencia, Spain; 2Manises Hospital, Valencia, Spain.
Background and objective: The upcoming new marketing presentations GLP1 analogues with a dosage more comfortable for patients, we wanted to revise the two we currently have on the market. The target of this study is to determinate glicated hemoglobin (HbA1c) at 6 months of treatment, changes in weight, body mass index (BMI) and tolerance.
Design and methods: Observational study that included 60 patients with diabetes mellitus type 2 followed in two Internal Medicine Service. The inclusion of patients was consecutive until achieve 30 patients with each of the treatments. Dose reached: Exenatide 10 μg twice daily and Liraglutide 1.2 mg daily. Determinations baseline and 6 months of treatment.
Results: – Baseline data: Exenatide/Liraglutide (weight 102.61/105.73, BMI 38.19/41.35, fasting glucose 189.56/183.35, HbA1c 8.9±0.6/8, 8±0, 8).
– After 6 months with exenatide, the weight loss was 2.99±5.12 kg (P<0.01), BMI reduction 1.36±1.18 kg/m2 (P<0.0001), of HbA1c 0.84%±2.06 (P<0.05) and of fasting glucose 23.63±59.12 mg/dl (P=0.09).
– After 6 months with Liraglutide, the weight loss was 3.18±3 kg (P<0.05), BMI reduction 1.18±1.67 kg/m2 (P<0.05), of HbA1c 0.9%±1.9 (P<0.05) and of fasting glucose 27.31±73.18 mg/dl (P<0.05).
– Further reduction BMI (0.18±0.77 kg/m2) in the group with Exenatide (P>0.05).
– Greater weight loss (0.19±2.18 kg), greater reduction fasting glucose (21.18±3.68 mg/dl) and a HbA1c greater reduction (0.06%±0.610) in the group with Liraglutide (P>0.05).
– 10 patients (33.3%) had gastrointestinal intolerance in the group treated with Exenatide and 4 (13.33%) in the group treated with Liraglutide (3 gastrointestinal intolerance and 1 dizziness).
– 5 dropouts for gastrointestinal intolerance and insuficient metabolic control in the group with Exenatide and 3 in the Liraglutide group.
Conclusions: Both drugs have very interesting clinical results in both efficiency (comparable to DPP4) and scarce secondary events. Notably Liraglutide currently offers an additional advantage for their a daily dosing.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more